Drug Economics Analysis

A forensic breakdown of why a specific biological treatment costs what it costs — and where the price could be different.

What It Is

Every biological drug carries a price tag that reflects manufacturing choices, regulatory paths, patent strategies, and market structures. Most of these cost drivers are invisible to prescribers, payers, and patients. We make them visible.

Our analysis traces the cost of a specific biologic from molecule to patient, identifying where value is created and where rent is extracted.

What You Get

Cost decomposition — manufacturing, regulatory, distribution, and margin breakdown per unit
Process bottleneck map — which production steps drive the most cost and why
Comparator analysis — how the cost structure compares to biosimilar and alternative pathways
Price sensitivity model — which cost drivers, if changed, would most reduce patient price
Policy leverage points — regulatory or structural changes that could shift the economics

Who It Serves

Healthcare regulators evaluating reimbursement policies for biologics
Health systems and insurers negotiating procurement terms
Biotech startups designing cost-competitive manufacturing processes
Patient advocacy groups building evidence-based cases for price reform